Oxurion Publishes 2021 Annual Report

March 25, 2022
Supporting Materials:

Leuven, BELGIUM, Boston, MA, US - March 25,2022 – 09.00 PM CET - Regulated Information – Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, published its annual report for the financial year 2021.

The annual report for the year ended 2021 is available in the “Investors” section of the Company’s website and can also be downloaded as a PDF.